Concepedia

Philip M. Roveto

PM

Statistics

Publications

8

Citations

518

H-Index

8

Active since

2008

Affiliations

Amgen (United States)(Current)

University of New Mexico

Philip M. Roveto is an author at Amgen (United States) specializing in drug discovery, medicinal chemistry, and pharmacology.

ORCID

Publications per year

2008–2020

8

Publications

8

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

Daqing Sun, Zhihong Li, Yosup Rew et al. · Journal of Medicinal Chemistry · 2014 · 296 citations · Full text

, , +7

Novel 2,3-Dihydro-1,4-Benzoxazines as Potent and Orally Bioavailable Inhibitors of Tumor-Driven Angiogenesis

Daniel S. La, Julie Belzile, James Bready et al. · Journal of Medicinal Chemistry · 2008 · 73 citations · Full text

, , +13

A Selective Prostaglandin E<sub>2</sub> Receptor Subtype 2 (EP2) Antagonist Increases the Macrophage-Mediated Clearance of Amyloid-Beta Plaques

Brian M. Fox, Hilary P. Beck, Philip M. Roveto et al. · Journal of Medicinal Chemistry · 2015 · 61 citations · Full text

, , +17

An intramolecular inverse electron demand Diels–Alder approach to annulated α-carbolines

Zhiyuan Ma, Feng Ni, Grace H. C. Woo et al. · Beilstein Journal of Organic Chemistry · 2012 · 27 citations · Full text

, , +11

Performance and diversity responses of nitrifying biofilms developed on varied materials and topographies to stepwise increases of aeration

Philip M. Roveto, Andrew J. Schuler · Bioresource Technology · 2019 · 18 citations

, , +14

1–5 of 8